Apoptosis pp 137-155 | Cite as

Proliferation Independent Activation of Programmed Cell Death as a Novel Therapy for Prostate Cancer

  • Yuzo Furuya
  • Richard S. Berges
  • Per Lundmo
  • John T. Isaacs
Part of the Pezcoller Foundation Symposia book series (PFSO, volume 5)


Since the work of Charles Huggins in the 1940s, it has been known that prostatic cancer often retains an androgen responsiveness for stimulation of its growth. Prostatic cancer is thus often highly responsive to androgen ablation therapy. Based upon this, patients with non-organ confined disease eventually require systemic androgen ablation therapy. Nearly all men with metastatic prostatic cancer treated with surgically or chemically induced castration have an initial, often dramatic, beneficial response to such androgen withdrawal therapy1. While this initial response is of substantial palliative value, essentially all treated patients eventually relapse to an androgen-insensitive state and succumb to the progression of their cancer unless they die of intercurrent disease first; cures, if any, are rare2. Because of this nearly universal relapse phenomenon, the annual death rate from prostatic cancer has not decreased at all over the subsequent 50 years since androgen withdrawal has become standard therapy3. Over the last 50 years, the superficially benign nature of androgen withdrawal therapy has tended to disguise the fact that metastatic prostatic cancer is still a fatal disease for which no therapy is available which effectively increases survival2,4.


Programme Cell Death Metastatic Prostatic Cancer Prostatic Cell Glandular Cell Androgen Ablation 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    The Leuprolide Study Group, Leuprolide versus diethylstilbestrol for metastatic prostatic cancer, New Engl. J. Med. 311–1281-1286 (1984).Google Scholar
  2. 2.
    H. Lepor, A. Ross, and P.C. Walsh, The influence of hormonal therapy on survival of men with advanced prostatic cancer, J. Urol. 128:335 (1982).PubMedGoogle Scholar
  3. 3.
    C. Boring, T. Squires, and T. Tong, Cancer Statistics, 1992, Ca-a Cancer Journal for Clinicians 42:19 (1993).CrossRefGoogle Scholar
  4. 4.
    D. Raghavan, Non-hormone chemotherapy for prostate cancer: principles of treatment and application to the testing of new drugs, Seminars in Oncology 15:371 (1988).PubMedGoogle Scholar
  5. 5.
    A.A Sinha, C.E. Blackhard, and U.S. Seal. A critical analysis of tumor morphology and hormone treatment in the untreated and estrogen treated responsive and refractory human prostatic carcinoma. Cancer 40:2836 (1977).PubMedCrossRefGoogle Scholar
  6. 6.
    G.R. Prout, B. Leiman, J.J. Daly, R.A. MacLoughlin, P.P. Griffin, and H.H Young, Endocrine changes after diethylstilbestrol therapy. Urology 7:148 (1976).PubMedCrossRefGoogle Scholar
  7. 7.
    J.T. Isaacs and D.S. Coffey, Adaptation vs selection as the mechanism responsible for the relapse of prostatic cancer to androgen ablation as studies in the Dunning R-3327 H adenocarcinoma, Cancer Research 41:5070 (1981).PubMedGoogle Scholar
  8. 8.
    J.T. Isaacs, Cellular factors in the development of resistance to hormonal therapy, In: Bruchovsky, N., Goldie, J, (eds), Drug and Hormone Resistance in Neoplasia I 139–156 , CRC Press, Boca Raton (1981).Google Scholar
  9. 9.
    J.T. Isaacs, The timing of androgen ablation therapy and/or chemotherapy in the treatment of prostatic cancer. Prostate 5:1 (1984).PubMedCrossRefGoogle Scholar
  10. 10.
    J.T. Isaacs, Relationship between tumor size and curability of prostate cancer by combined chemohormonal therapy. Cancer Research 49:6290 (1989).PubMedGoogle Scholar
  11. 11.
    S.E. Shackney, G.W. McCormack, and G.J. Cuchural, Growth rate patterns of solid tumors and their relationship to responsiveness to therapy. Annals of Internal Medicine 89:107 (1978).PubMedCrossRefGoogle Scholar
  12. 12.
    B. Helpap, R. Steins, and P. Bruhl, Autoradiographic in vitro investigations on prostatic tissue with C-14 and H-3 thymidine double labeling method, Beitr. Pathol. anat. Allg. Pathol., 151:65 (1974).CrossRefGoogle Scholar
  13. 13.
    J. S. Meyers, G. Sufrin, and S.A. Maring, Proliferation activity of benign human prostate, prostatic adenocarcinoma and seminal vesicle evaluated by thymidine labeling, J. Urol., 128:1353 (1982).Google Scholar
  14. 14.
    R. Nemoto, K. Hattori, K. Uchida, T. Shimazui, Y. Nishijima, K. Koiso, and M. Harada, S-phase fraction of human prostate adenocarcinoma studies with in vivo bromodeoxyuridine labeling, Cancer (Phila.), 66:509 (1990).CrossRefGoogle Scholar
  15. 15.
    M.V. Sadi and E.R. Barrack, Determination of growth fraction in advanced prostate cancer by Ki-67 immunostaining and its relationship to the time to tumor progression after hormonal therapy, Cancer (Phila.), 67:3065 (1991).CrossRefGoogle Scholar
  16. 16.
    J. Folkman, What is the evidence that tumors are angiogenesis-dependent? J. Natl. Cancer Inst. 82:4 (1990).PubMedCrossRefGoogle Scholar
  17. 17.
    A.H. Wyllie, J.F.R. Kerr, and A.R. Currie, Cell death: the significance of apoptosis, International Reviews of Cytology 68:251 (1980).CrossRefGoogle Scholar
  18. 18.
    J.F.R. Kerr, A.H. Wyllie, and A.R. Currie. Apoptosis: a basic biological phenomenon with wide ranging implications in tissue kinetics. Br. J. Cancer, 26:239 (1972).PubMedCrossRefGoogle Scholar
  19. 19.
    S.R. Umansky, B.A. Korol, and P.A. Nelipovich, In vivo DNA degradation in thymocytes of γ-irradiated or hydrocortisone-treated rats, Biochim. Biophys. Acta, 655:9 (1981).CrossRefGoogle Scholar
  20. 20.
    A.H. Wyllie, R.G. Morris, A.L. Smith, and D. Dunlop, Chromatin cleavage in apoptosis: association with condensed chromatin morphology and dependence on macromolecular synthesis, J. Pathol., 142:66(1984).CrossRefGoogle Scholar
  21. 21.
    N. Kyprianou and J.T. Isaacs, Activation of programmed cell death in the rat ventral prostate after castration, Endocrinology, 122:552 (1988).PubMedCrossRefGoogle Scholar
  22. 22.
    H.F. English, N. Kyprianou, and J.T. Isaacs, Relationship between DNA fragmentation and apoptosis in the programmed cell death in the rat prostate following castration, Prostate, 15:233 (1989).PubMedCrossRefGoogle Scholar
  23. 23.
    N. Kyprianou, H.F. English, and J.T. Isaacs, Activation of a Ca2+-Mg2+-dependent endonuclease as an early event in castration-induced prostatic cell death, Prostate, 13:103 (1988).PubMedCrossRefGoogle Scholar
  24. 24.
    N. Kyprianou, H.F. English, and J.T. Isaacs, Programmed cell death during regression of PC-82 human prostate cancer following androgen ablation, Cancer Res., 50:3748 (1990).PubMedGoogle Scholar
  25. 25.
    J.T. Isaacs, Antagonistic Effect of Androgen on Prostatic Cell Death, The Prostate 5:545 (1984).PubMedCrossRefGoogle Scholar
  26. 26.
    N. Kyprinaou and J.T. Isaacs, Biological Significance of Measurable Androgen Levels in the Rat Ventral Prostate Following Castration, The Prostate 10:313 (1987).CrossRefGoogle Scholar
  27. 27.
    A.E. Pegg, D.H. Lockwood, and H.G. Williams-Ashman, Concentrations of Putrescine and Polyamines and their Enzymic Synthesis during Androgen-Induced Prostatic Growth, Biochem. J. 117:17(1970).PubMedGoogle Scholar
  28. 28.
    P. Martikainen and J. Isaacs, Role of Calcium in the Programmed Death of Rat Prostatic Glandular Cells, The Prostate 17:175 (1990).PubMedCrossRefGoogle Scholar
  29. 29.
    N. Kyprianou and J.T. Isaacs, Expression of transforming growth factor-ß in the rat ventral prostate during castration induced programmed cell death, Mol. Endocrinol. 3:1515 (1989).Google Scholar
  30. 30.
    N. Kyprianou and J.T. Isaacs, Identification of a cellular receptor for transforming growth factor-ß in rat ventral prostate and its negative regulation by androgens, Endocrinol. 123:2124 (1988b).CrossRefGoogle Scholar
  31. 31.
    P. Martikainen, N. Kyprianou, and J.T. Isaacs, Effect of Transforming Growth Factor-ß1 on Proliferation and Death of Rat Prostatic Cells, Endocrinol. 127:2963 (1990).CrossRefGoogle Scholar
  32. 32.
    R.D. Synder, Polyamine depletion is associated with altered chromatin structure in HeLa cells, Biochem. J. 260:697 (1989).Google Scholar
  33. 33.
    B. Brüne, P. Hartzeil, P. Nicotera, and S. Orrenius, Spermine prevents endonuclease activation and apoptosis in thymocytes, Exp. Cell Res. 195:323 (1991).PubMedCrossRefGoogle Scholar
  34. 34.
    L.W.K. Chung and D.S. Coffey, Biochemical characterization of prostatic nuclei I. androgen-induced hanges in nuclear proteins, Biochimica. Biophysica. Acta 247:570 (1971).CrossRefGoogle Scholar
  35. 35.
    J.F.R. Kerr and J. Searle, Deletion of cells by apoptosis during castration-induced involution of the rat prostate, Virchows. Arch. [Cell Pathol] 13:87 (1973).Google Scholar
  36. 36.
    Y. Furuya and J.T. Isaacs, Differential gene regulation during programmed death (Apoptosis) versus proliferation of prostatic glandular cells induced by androgen manipulation, in press (1993).Google Scholar
  37. 37.
    V.E. Quarmby, W.C. Beckman, Jr., E.M. Wilson, and F.S. French, Androgen regulation of c-myc messenger ribonucleic acid levels in rat ventral prostate, Mol. Endocrinol. 1:865 (1987).PubMedCrossRefGoogle Scholar
  38. 38.
    C. Chang, A.G. Saltzman, N.S. Sorensen, R.A. Hiipakka, and S. Liao, Identification of glutathione S-transferase Yb1 mRNA as the androgen repressed mRNA by cDNA cloning and sequence analysis, J. Biol. Chem. 262:11901 (1987).PubMedGoogle Scholar
  39. 39.
    M.L. Montpetit, K.R. Lawless, and M. Tenniswood, Androgen Repressed Messages in the Rat Ventral Prostate, Prostate 8:25 (1986).PubMedCrossRefGoogle Scholar
  40. 40.
    R. Buttyan, Z. Zakeri, R. Lockshin, and D. Wolgemuth, Cascade induction of c-fos, c-myc and heat shock 70K transcripts during regression of the rat ventral prostate gland, Mol. Endocrinol., 2:650 (1988).PubMedCrossRefGoogle Scholar
  41. 41.
    R. Buttyan, C.A. Olsson, J. Pintar, C. Chang, M. Bandyk, P-Y Ng, and I.S. Sawczuk, Induction of the TRPM-2 gene in cells undergoing programmed death, Mol. Cell Biol. 9:3473 (1989).PubMedGoogle Scholar
  42. 42.
    D.R. Dowd, P.N. MacDonald, B.S. Komm, M.R. Haussler, and R. Miesfeld, Evidence for early induction of calmodulin gene expression in lymphocytes undergoing glucocorticoid-mediated apoptosis, J. Biological Chemistry 266:18423 (1991).Google Scholar
  43. 43.
    L. Fesus, V. Thomazy, and A. Falus, Induction and activation of tissue transglutaminase during programmed cell death, FEBS Lett. 224:104 (1989).CrossRefGoogle Scholar
  44. 44.
    D.S. Coffey, J. Shimazaki, and H.G. Williams-Ashman, Polymerization of deoxyribonucleotides in relation to androgen-induced prostatic growth, Arch. Biochem. Biophys. 124:184 (1968).CrossRefGoogle Scholar
  45. 45.
    Y. Gavrieli, Y. Sherman, and S.A. Ben-Sasson, Identification of Programmed Cell Death In Situ via Specific Labeling of Nuclear DNA Fragmentation, J. Cell Biol. 119:493 (1992).PubMedCrossRefGoogle Scholar
  46. 46.
    R. S. Berges, Y. Furuya, L. Remington, H.F. English, T. Jacks, and J.T. Isaacs, Cell proliferation, DNA repair, and p53 function are not required for programmed death of prostatic glandular cells induced by androgen ablation, Proc. Natl. Acad. Sci. (USA), (in press, 1993).Google Scholar
  47. 47.
    R. Stiens and Helpap, Regressive changes in the prostate after castration. A study using histology, morphometrics and autoradiography with special reference to apoptosis, Pathol. Res. Pract. 172:73 (1981).PubMedCrossRefGoogle Scholar
  48. 48.
    G.S. Evans and J.A. Chandler, Cell proliferation studies in the rat prostate: II. The effects of castration and androgen replacement upon basal and secretory cell proliferation, Prostate 11:339 (1987).PubMedCrossRefGoogle Scholar
  49. 49.
    H.F. English, J.R. Drago, and R.J. Santen, Cellular response to androgen depletion and repletion in the rat ventral prostate: Autoradiography and morphometric analysis, The Prostate 7:41 (1985).PubMedCrossRefGoogle Scholar
  50. 50.
    S. Lowe, EM. Schmitt, S.W. Smith, B.A. Osborne, and T. Jacks, p53 is required for radiation induced apoptosis in mouse thymocytes, Nature 362:847 (1993).PubMedCrossRefGoogle Scholar
  51. 51.
    R. Berges and J.T. Isaacs, Programming events in the regulation of cell proliferation and death, Clinical Chemistry 39:2 (1993).Google Scholar
  52. 52.
    N. Kyprianou and J.T. Isaacs, Thymine-less death in androgen independent prostatic cancer cells, Biochem. Biophys. Res. Commun. 165:73 (1989).CrossRefGoogle Scholar
  53. 53.
    P. Martikainen, N. Kyprianou, R.W. Tucker and J.T. Isaacs, Programmed death of non-proliferating androgen independent prostatic cancer cells, Cancer Res. 51:4693 (1991).PubMedGoogle Scholar
  54. 54.
    S.B. Christensen, E. Norup E and U. Rasmussen, Chemistry and structure-activity relationship of the histamine secretagogue Thapsigragin and related compounds, In: Natural Products and Drug Development (Editors: P. Krogsgaard-Larsen, S. Brogger Christensen, H. Kofod) pp. 405 (1993).Google Scholar
  55. 55.
    U. Rasmussen, S.B. Christensen, and F. Sandberg, Thapsigargin and thapsigargicin, two new histamine liberators from Thapsia garganica. L. Acta. Pharm. Suec. 15, 133 (1978).Google Scholar
  56. 56.
    O. Thastrup, P.J. Cullen, B.K. Dr_bak, M.R. Hanley, and A.P. Dawson, Thapsigargin, a tumor promoter, discharges intracellular Ca2+ stores by specific inhibition of the endoplasmic reticulum Ca2+-ATPase, Proc. Natl. Acad. Sci. USA, 87:2466 (1990).PubMedCrossRefGoogle Scholar
  57. 57.
    J. Lytton, M. Westlin, and M.R. Haley, Thapsigargin inhibits the sarcoplasmic or endoplasmic reticulum Ca-ATPase family of calcium pumps, J. Biol. Chem. 266:17067 (1991).PubMedGoogle Scholar
  58. 58.
    A. Christensson, C.B. Laurell, and H. Lilja, Enzymatic activity of the prostate-specific antigen and its reactions with extracellular serine proteinase inhibitors, Europe J. Biochem. 194:755 (1990).CrossRefGoogle Scholar
  59. 59.
    L.D. Papsidero, M. Kuriyama, M.C. Want, J. Horoszewicz, S.S. Leong, L. Valenzuela, et al. Prostate antigen: a marker for human prostate epithelial cells, J. Natl. Cancer Inst. 66:37 (1981).PubMedGoogle Scholar
  60. 60.
    H. Lilja. C. Christensson, U. Dahlen, M-T. Martikainen, O. Nilsson, K. Pettersson, et al, Prostate-specific antigen in human srum occurs predominately in complex with α1-antichymotrypsin, Clin. Chem. 37:618(1991).Google Scholar

Copyright information

© Springer Science+Business Media New York 1994

Authors and Affiliations

  • Yuzo Furuya
    • 1
  • Richard S. Berges
    • 1
  • Per Lundmo
    • 1
  • John T. Isaacs
    • 1
  1. 1.The Johns Hopkins Oncology Center and Department of UrologyJohns Hopkins University School of MedicineBaltimoreUSA

Personalised recommendations